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516authors conclude that the combination of vitamin K
antagonists (VKA) and clopidogrel may serve as a
valuable alternative to a triple antithrombotic
regimen also including aspirin, based on the results
of 1 small randomized controlled trial and a large
nationwide registry (2,3).
In a recent joint consensus document frommultiple
European Associations, endorsed by the Heart Rhythm
Society and Asia-Paciﬁc Heart Rhythm Society, dual
therapy consisting of VKA and clopidogrel “may” (i.e.,
Class IIb) or even “should” (i.e., Class IIa) be consid-
ered in patients with stable coronary artery disease
undergoing stenting with variable lengths and
strengths of recommendation depending on indi-
vidual stroke (i.e., CHA2DS2-VASc score ¼ 1 or $2) and
bleeding (i.e., HAS-BLED ¼ 0 to 2 or $3) risks (4). We
underscore that aspirin should not be dropped in
patients at low bleeding risk on long-term VKA
therapy in the context of an acute coronary syndrome
(ACS)—with or without stenting, and for at least the
ﬁrst 6 months—because: 1) the beneﬁt of dual
antiplatelet therapy in ACS patients is established (5);
and 2) the WOEST (What is the Optimal antiplatElet
and anticoagulant therapy in patients with oral
anticoagulation and coronary StenTing) trial included
only a minority (w25%) of patients with an ACS (2).
Other limitations of the WOEST trial are also evident,
including the prolonged period (12 months) of triple
therapy and the endpoint driven by minor bleeds
(with major bleeds not different between triple and
dual therapy) (4).
In the Danish registry, where only ACS patients
where included by study design, the adjusted risk of
all-cause mortality compared with aspirin mono-
therapy was numerically, albeit not signiﬁcantly,
lower with triple antithrombotic therapy (i.e., hazard
ratio: 1.04) than with a dual therapy regimen of VKA
and clopidogrel (i.e., hazard ratio 1.22), whereas the
risk of fatal and nonfatal bleeding was signiﬁcantly
increased with both regimens (3). As far as the
duration of triple antithrombotic therapy is
concerned, the joint European document points out
that the period where maximum antithrombotic
protection should be given (in patients at low or
moderate bleeding risk) corresponds to the ﬁrst 6
months after the onset of an ACS and/or a second-
generation drug-eluting stent implantation (4).
This has been recently found to be consistent
with the 2014 European guidelines for myocardial
revascularization (5) and the newly presented ISAR-
TRIPLE (Intracoronary Stenting and Antithrombotic
Regimen—Testing of a six-week versus a six-month
clopidogrel treatment Regimen In Patients with
concomitant aspirin and oraL anticoagulant therapyfollowing drug-Eluting stenting) study (presented at
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Don’t Drop Aspirin Just YetWe thank Drs. Capodanno and Lip for their interest in
and valuable comments on our recent review (1) on
triple therapy for atrial ﬁbrillation (AF) and
percutaneous coronary intervention (PCI).
The conclusion of our review was that it might be a
reasonable option to treat with a combination of
vitamin K antagonists (VKA) and clopidogrel, which
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517is the only combination having shown favorable
results compared with triple therapy (TT), based on
the results of a randomized trial and a nationwide
registry (1).
Drs. Capodanno and Lip highlight the recent
guideline and consensus documents from multiple
European associations (2,3) and state that aspirin
should not be dropped in patients with low
bleeding risk and acute coronary syndrome (ACS).
We acknowledge the great work done by the au-
thors of both guidelines and this consensus docu-
ment (2,3). Of course, we recognize the limitations
of the WOEST (What is the Optimal antiplatElet and
anticoagulant therapy in patients with oral anti-
coagulation and coronary StenTing) trial (only one-
quarter of patients with ACS) and the Danish reg-
istry, and these limitations were extensively
described in our recently published review (1,4,5).
On the other hand, the Class IIA recommendation in
the European consensus and guidelines to use TT in
patients with AF and PCI is made on a Level of
Evidence: C, which is “consensus of opinion of the
experts and/or small studies, retrospective studies,
registries.” Unfortunately, there is not one rando-
mised trial favoring TT.
Furthermore, Drs. Capodanno and Lip state that the
number of major bleeding events in the WOEST trial
did not differ. Again, we recognize the limitations of
theWOEST trial in thatmost bleedings prevented were
minor and minimal. However, Capodanno and Lip’s
statement is not completely true. Although there was
no signiﬁcant difference in Thrombolysis In Myocar-
dial Infarction major bleeding events, there was,
however, a signiﬁcant difference in the newer, but
widely accepted, Bleeding Academic Research Con-
sortium 3 bleeding classiﬁcation, which corresponds
with major bleeding (1,4).
Moreover, the Danish registry containing 12,000
patients provides sufﬁcient power to state that the
combination of VKA and clopidogrel is safe with re-
gard to thrombotic and thromboembolic complica-
tions such as myocardial infarction and ischemic
stroke, which was a major concern because of the lack
of power regarding the ischemic endpoints in the
WOEST trial (1,5).
In patients with AF and ACS, our conclusion was
backed up by the recently presented AVIATOR reg-
istry containing 859 patients, which also showed
fewer bleeding events in patients without aspirin,
whereas no difference in the ischemic endpoints was
observed in patients treated with dual therapy as
compared with TT (presented at Transcatheter Car-
diovascular Therapeutics, September 2014, Wash-
ington, DC).Finally, the authors attract attention to the re-
sults of the ISAR-TRIPLE (Intracoronary Stenting
and Antithrombotic Regimen-Testing of a six-week
versus a six-month clopidogrel treatment Regimen
In Patients with concomitant aspirin and oraL
anticoagulant therapy following drug-Eluting stent-
ing) trial (presented at Transcatheter Cardiovascular
Therapeutics, September 2014, Washington, DC).
However, the design of this trial was vitally
different from the WOEST trial because aspirin was
continued in ISAR-TRIPLE, whereas aspirin was
stopped in WOEST with the aim to reduce bleeding
events. Additionally, clopidogrel was stopped early
after stenting in ISAR-TRIPLE to reduce bleeding,
whereas previous publications show clopidogrel to
be essential in preventing stent thrombosis. The
hypothesis of the WOEST trial was that clopidogrel
needed to be continued to adequately prevent stent
thrombosis (1,5).
In conclusion, we agree with Drs. Capodanno and
Lip that the burden of evidence favoring the combi-
nation VKA þ clopidogrel is still limited; on the other
hand, we also have to acknowledge the fact that there
is not one randomized trial favoring TT. Therefore,
we will have to wait for the results of the large
ongoing randomized trials, such as the PIONEER AF
(A Study Exploring Two Strategies of Rivaroxaban
and One of Oral Vitamin K Antagonist in Patients With
Atrial Fibrillation Who Undergo Percutaneous Coro-
nary Intervention) and RE-DUAL PCI (Evaluation of
Dual Therapy With Dabigatran vs. Triple Therapy
With Warfarin in Patients With AF That Undergo a PCI
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